All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the Lymphoma Coalition.

The Lymphoma Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

Introducing

Now you can personalise
your Lymphoma Hub experience!

Bookmark content to read later

Select your specific areas of interest

View content recommended for you

Find out more
  TRANSLATE

The Lymphoma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Lymphoma Hub cannot guarantee the accuracy of translated content. The Lymphoma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

Steering CommitteeAbout UsNewsletterContact
LOADING
You're logged in! Click here any time to manage your account or log out.
LOADING
You're logged in! Click here any time to manage your account or log out.

The Lymphoma & CLL Hub is an independent medical education platform, sponsored by Beigene and Roche, and supported through educational grants from Bristol Myers Squibb, Ipsen Biopharmaceuticals, Pfizer, and Pharmacyclics LLC, an AbbVie Company and Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC. View funders.

2019-06-03T15:58:26.000Z

What are the driving forces in patient selection for CAR T-cell therapy in aggressive lymphoma?

Jun 3, 2019
Share:

Bookmark this article

At the 2019 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, US, Matthew Alexander Lunning, University of Nebraska, discusses the factors which influence the selection of patients with aggressive lymphoma who are eligible for CAR T-cell therapy.

Dr. Lunning explains that there are about 27,000 new cases of aggressive lymphoma per year, and with each line of therapy, the effectiveness of that therapy goes down. To date, CAR T-cell therapy is approved for second line treatment of relapsed/refractory diffuse large B-cell lymphoma. Dr. Lunning also explains the results of the ZUMA-1 trial, that showed a 2-year progression-free survival in about 39% of patients, and further explains the many factors involved with patient selection. Dr. Lunning urges physicians to consider if patients should have an intervention or consultation to look at whether CAR T-cell therapy may be a treatment option for their patients.

What are the driving forces in patient selection for CAR T-cell therapy in aggressive lymphoma?

Understanding your specialty helps us to deliver the most relevant and engaging content.

Please spare a moment to share yours.

Please select or type your specialty

  Thank you

Your opinion matters

HCPs, what is your preferred format for educational content on the Lymphoma Hub?
26 votes - 5 days left ...

Newsletter

Subscribe to get the best content related to lymphoma & CLL delivered to your inbox